Politicians are forgetting about a bigger piece of the drug development puzzle: a new type of biopharma. In a recent opinion piece, The Wall Street Journal takes a look at the FDA's recent approval of Attruby, discussing how the new treatment is breaking the big pharma monopoly in #heartdisease. Read more below.
Keep up this level of innovation BBIO!
Very informative
interesting perspective!
Insightful.
Doctoral Researcher in Neuroscience & Pharmacology | Clinical Pharmacy Specialist |Accredited CPD Provider | Medical Speaker and Trainer | Expert in Medication Safety & Pharmacovigilance
🌟 Drug Repositioning🌟 🌐 It's also known as "drug repurposing" or "drug reprofiling". Simply, exploring new uses for existing medications so, it is giving new indications for existing FDA-approved medications that were not previously referenced and not currently prescribed or investigated. Repurposed drugs benefit from existing pharmacological and safety data, expediting clinical trials and FDA review. so .. we can potentially discover innovative treatments faster and more cost-effectively than developing new drugs from scratch. 🚀💊 this approach uncovers new mechanisms of action for existing compounds or finds new uses for established targets in different disease areas.🧠💡 #DrugRepositioning #DrugRepurposing #Medical #Healthcare #indication #Pharmaceutical #Research Good Read: Jourdan, J. P., Bureau, R., Rochais, C., & Dallemagne, P. (2020). Drug repositioning: a brief overview. Journal of Pharmacy and Pharmacology, 72(9), 1145-1151.
Quality QMS│ Business Development │ Regulatory Affairs │ COFEPRIS │ Medical Devises & Pharma│ Regulatory Strategies │ Project Manager
Interesting read for business development and pharma developers. Decision-making in identifying high-demand molecules is crucial for strategic growth and competitive advantage. This article provides valuable insights into market opportunities, helping companies align their R&D and marketing strategies to meet emerging needs. Understanding these trends can significantly impact the success of new product launches and drive innovation in the pharmaceutical industry.
Key trends in the small molecule injectables market up to 2033 include advancements in technology and drug delivery systems, research says. #drugdevelopment #smallmolecule #EPRTalks
Explore how advancements in pharmacogenomic testing are revolutionizing drug development, enhancing precision medicine, and improving patient outcomes. https://lnkd.in/gPE-vZxS #apgxa #pgx #pharmacogenomics #drugdevelopment
📰 ✨✔We are thrilled to announce the publication of our latest article 'Oromucosal spray products – Viscosity impact on spray performance evaluation' in the Journal of Drug Delivery Science and Technology. 🔬This research aims to highlight the significance of investigating quality attributes and their impact on spray performance from the initial stages of development. 👩🔬The authors of this research paper are Francisca Bastos Silva, Andreia Tabanez, Maria Aquino, Antonio Lucas Nunes and Sergio Simoes. 👉 Follow the link to see this work: https://lnkd.in/dTjf2qjM #witheyesetonthefuture #followbluepharma #Bluepharma #Bluepharma23anos #Bluepharmaacelera2030 #pharmaceuticalindustry #pharmaceutical #industry #indústriafarmacêutica #innovation #development #technology #health #pharmaceuticals #generics #CRDMO #CDMO #CMO #complexinjectabels #highpotentproducts #Pharma #lifescience #oncology #research #pharma
President @ American Pharmacogenomics Association (expanded to include Multi-Omics & Biomedical Informatics)
Explore how advancements in pharmacogenomic testing are revolutionizing drug development, enhancing precision medicine, and improving patient outcomes. https://lnkd.in/gM8nwgER #apgxa #pgx #pharmacogenomics #drugdevelopment
🔬 Exciting News in Healthcare Innovation! 2024 has been a landmark year for healthcare, thanks to the FDA’s Center for Drug Evaluation and Research (CDER). With a commitment to advancing public health, CDER has approved a range of groundbreaking new drugs and therapeutic biological products, opening new doors for patient care and treatment options. Among the highlights are several new molecular entities (NMEs) that promise to bring transformative therapies to patients across various conditions: • Duvyzat (givinostat) • Tryvio (aprocitentan) • Rezdiffra (resmetirom) • Tevimbra (tislelizumab-jsgr) • Letybo (letibotulinumtoxinA-wlbg) • Exblifep (cefepime, enmetazobactam) • Zelsuvmi (berdazimer) These approvals underscore CDER’s expertise in guiding drug developers through the intricate process of bringing innovative treatments from the lab to the clinic. Each product represents a step forward in offering new solutions for diseases and conditions that challenge patients daily. For professionals in healthcare, pharmaceuticals, and biotechnology, these developments are not just advancements in medical science; they are potential opportunities for collaboration, research, and improvement in patient outcomes. Let’s discuss how these innovations can shape the future of healthcare and contribute to a healthier tomorrow. #healthcareinnovation #FDAapproval #newdrugdevelopment #CDER #pharmaceuticals #biotech #patientcare #2024HealthcareMilestones #shenclinicalservices
Independent, Previous Senior Vice President and Head of Translational Sciences at Bayer Pharmaceuticals
The Importance of Good Data for Decision-making in Pharmaceutical Research and Development (R&D) Decision-making in pharmaceutical R&D is integral to the success of the industry. It impacts everything from resource utilization and risk management to innovation, regulatory compliance, and patient outcomes. Efficient decision-making processes accelerate timelines by prioritizing projects, streamlining research activities, and making timely go/no-go decisions, which is crucial for bringing new therapies to market faster. Making informed decisions based on scientific, clinical, and market data fosters innovation. It ensures that the R&D pipeline is aligned with current scientific advancements and market needs. Good, i.e. robust and reliable data is crucial for decision-making. It ensures that decisions are based on factual, reliable information. Inaccurate or incomplete data can lead to poor decisions that might have adverse effects on an organization or project. Analyzing good data allows for the identification of patterns, trends, and insights that might not be apparent otherwise. This can inform strategic planning and help predict future outcomes. In particular in the early phase of research and development projects are associated with a high number of uncertainties and unknowns which makes it difficult to predict the outcome of a project. In fact, the failure rate is very high because during the early phase of development only limited data have been generated. This underlines the need for having access to all available data from all sources. Enabled by an ever-expanding arsenal of model systems, analysis methods, libaries of chemical and biological compounds, the amount of data generated during drug discovery and early development programmes has never been greater and it is therefore imperative that the learnings from these data investments are maximized to enable better predictions thereby increasing the likelyhood of technical success. Such approaches not only rely on data generated specifically within a given project to learn from, they also evaluate all other available data from different data sources and relevance to the question at hand. In this context, data sources like PharmaPendium are playing a crucial role. The search, analytics, and predictive capabilities in the platform help accelerate drug development approvals, including drug safety tests, clinical trial design, and post-market surveillance. But also in the early phase the information about competitor drugs, about the mode of action, about relevant data sets including activity, efficacy, pharmacokinetics, toxicological liabilities, and last but not least potential regulatory implications will guide researchers when it comes to selecting projects with the highest potential of success which is one of the most important decisions in pharmaceutical companies. #pharma #drugdiscovery #elsevier
#Pharmapendium provide High quality grade regulatory data that are essential for successful drug development. To know more about how data drives decision-making read the post of Eckhard von Keutz that spent 38 years leading dug development safety teams and projects at Bayer.
Independent, Previous Senior Vice President and Head of Translational Sciences at Bayer Pharmaceuticals
The Importance of Good Data for Decision-making in Pharmaceutical Research and Development (R&D) Decision-making in pharmaceutical R&D is integral to the success of the industry. It impacts everything from resource utilization and risk management to innovation, regulatory compliance, and patient outcomes. Efficient decision-making processes accelerate timelines by prioritizing projects, streamlining research activities, and making timely go/no-go decisions, which is crucial for bringing new therapies to market faster. Making informed decisions based on scientific, clinical, and market data fosters innovation. It ensures that the R&D pipeline is aligned with current scientific advancements and market needs. Good, i.e. robust and reliable data is crucial for decision-making. It ensures that decisions are based on factual, reliable information. Inaccurate or incomplete data can lead to poor decisions that might have adverse effects on an organization or project. Analyzing good data allows for the identification of patterns, trends, and insights that might not be apparent otherwise. This can inform strategic planning and help predict future outcomes. In particular in the early phase of research and development projects are associated with a high number of uncertainties and unknowns which makes it difficult to predict the outcome of a project. In fact, the failure rate is very high because during the early phase of development only limited data have been generated. This underlines the need for having access to all available data from all sources. Enabled by an ever-expanding arsenal of model systems, analysis methods, libaries of chemical and biological compounds, the amount of data generated during drug discovery and early development programmes has never been greater and it is therefore imperative that the learnings from these data investments are maximized to enable better predictions thereby increasing the likelyhood of technical success. Such approaches not only rely on data generated specifically within a given project to learn from, they also evaluate all other available data from different data sources and relevance to the question at hand. In this context, data sources like PharmaPendium are playing a crucial role. The search, analytics, and predictive capabilities in the platform help accelerate drug development approvals, including drug safety tests, clinical trial design, and post-market surveillance. But also in the early phase the information about competitor drugs, about the mode of action, about relevant data sets including activity, efficacy, pharmacokinetics, toxicological liabilities, and last but not least potential regulatory implications will guide researchers when it comes to selecting projects with the highest potential of success which is one of the most important decisions in pharmaceutical companies. #pharma #drugdiscovery #elsevier
1 in 10 of us live with diseases that lack approved therapies, despite many of these conditions sharing similar underlying mechanisms treatable with existing drugs. This begs a critical question: Why aren't we harnessing the full potential of available medications? Several barriers stand in the way: 1. The absence of a centralized database curating the most effective drug repurposing insights leaves valuable knowledge fragmented and underutilized. 2. No dedicated organization oversees the comprehensive application of drugs across all possible disease indications, limiting systematic exploration of their potential. 3. The current incentive structures for pharmaceutical companies do not adequately encourage the repurposing of existing drugs, especially for conditions that are less profitable or widespread. These challenges underscore a pressing need for systemic change. At Every Cure we are addressing these obstacles to open new pathways to treatment for millions. How can we collaborate across sectors to ensure that every drug's full therapeutic potential is explored and utilized? #drugdevelopment #drugdiscovery #drugsafety #pharma
Never miss a beat on the app
Don’t have the app? Get it in the Microsoft Store.
Open the app
Thought Leader Liaison at Alexion
1dInteresting article, thanks for posting Andrea! Happy Holidays!